426 related articles for article (PubMed ID: 21909397)
1. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.
Wilson EB; El-Jawhari JJ; Neilson AL; Hall GD; Melcher AA; Meade JL; Cook GP
PLoS One; 2011; 6(9):e22842. PubMed ID: 21909397
[TBL] [Abstract][Full Text] [Related]
2. An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression.
Fujii R; Jochems C; Tritsch SR; Wong HC; Schlom J; Hodge JW
Cancer Immunol Immunother; 2018 Apr; 67(4):675-689. PubMed ID: 29392336
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of the effects of inhibitory cytokines on human natural killer cells and the mechanistic features of transforming growth factor-beta.
Lee HM; Kim KS; Kim J
Cell Immunol; 2014 Jul; 290(1):52-61. PubMed ID: 24879062
[TBL] [Abstract][Full Text] [Related]
4. TGF-β regulated leukemia cell susceptibility against NK targeting through the down-regulation of the CD48 expression.
Huang CH; Liao YJ; Chiou TJ; Huang HT; Lin YH; Twu YC
Immunobiology; 2019 Sep; 224(5):649-658. PubMed ID: 31421859
[TBL] [Abstract][Full Text] [Related]
5. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
[TBL] [Abstract][Full Text] [Related]
6. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.
Viel S; Marçais A; Guimaraes FS; Loftus R; Rabilloud J; Grau M; Degouve S; Djebali S; Sanlaville A; Charrier E; Bienvenu J; Marie JC; Caux C; Marvel J; Town L; Huntington ND; Bartholin L; Finlay D; Smyth MJ; Walzer T
Sci Signal; 2016 Feb; 9(415):ra19. PubMed ID: 26884601
[TBL] [Abstract][Full Text] [Related]
7. Role of c-Myb in the regulation of natural killer cell activity.
Shin HW; Lee YJ; Kim J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2807-2813. PubMed ID: 30103947
[TBL] [Abstract][Full Text] [Related]
8. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
[TBL] [Abstract][Full Text] [Related]
9. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of interleukin-12- and interleukin-15-induced natural killer cell activation by interleukin-4.
Salvucci O; Mami-Chouaib F; Moreau JL; Thèze J; Chehimi J; Chouaib S
Eur J Immunol; 1996 Nov; 26(11):2736-41. PubMed ID: 8921963
[TBL] [Abstract][Full Text] [Related]
11. Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10.
Cui C; Feng H; Shi X; Wang Y; Feng Z; Liu J; Han Z; Fu J; Fu Z; Tong H
Int Immunopharmacol; 2015 Jul; 27(1):110-21. PubMed ID: 25978851
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.
Ng S; Deng J; Chinnadurai R; Yuan S; Pennati A; Galipeau J
Cancer Res; 2016 Oct; 76(19):5683-5695. PubMed ID: 27488533
[TBL] [Abstract][Full Text] [Related]
13. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.
Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Österborg A; Lundqvist A
Eur J Immunol; 2015 Jun; 45(6):1783-93. PubMed ID: 25773885
[TBL] [Abstract][Full Text] [Related]
15. Regulation of NK cell functions by TGF-beta 1.
Bellone G; Aste-Amezaga M; Trinchieri G; Rodeck U
J Immunol; 1995 Aug; 155(3):1066-73. PubMed ID: 7636180
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.
Otegbeye F; Ojo E; Moreton S; Mackowski N; Lee DA; de Lima M; Wald DN
PLoS One; 2018; 13(1):e0191358. PubMed ID: 29342200
[TBL] [Abstract][Full Text] [Related]
17. The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia.
Rouce RH; Shaim H; Sekine T; Weber G; Ballard B; Ku S; Barese C; Murali V; Wu MF; Liu H; Shpall EJ; Bollard CM; Rabin KR; Rezvani K
Leukemia; 2016 Apr; 30(4):800-11. PubMed ID: 26621337
[TBL] [Abstract][Full Text] [Related]
18. Unique phenotype of human uterine NK cells and their regulation by endogenous TGF-beta.
Eriksson M; Meadows SK; Wira CR; Sentman CL
J Leukoc Biol; 2004 Sep; 76(3):667-75. PubMed ID: 15178706
[TBL] [Abstract][Full Text] [Related]
19. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
20. Regulation of natural killer cell activity by transforming growth factor-beta and prostaglandin E2.
Malygin AM; Meri S; Timonen T
Scand J Immunol; 1993 Jan; 37(1):71-6. PubMed ID: 8380302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
